• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ReCor receives CE mark for ultrasound-based renal denervation system

ReCor receives CE mark for ultrasound-based renal denervation system

January 24, 2013
CenterWatch Staff

ReCor Medical, a private venture-backed, early-stage company focused on ultrasound catheter technology, has received CE mark for its next-generation Paradise system, a minimally invasive 6Fr over-the-wire (OTW) ultrasound device for treating resistant high blood pressure.

The Gen 1 Paradise system previously received CE mark just over one year ago. The Gen 2 Paradise system considerably enhances efficiency while making the procedure easier and quicker. It is the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency (RF), energy. Additionally, the treatment parameters of Gen 2 have been further enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and efficiently treating the nerves circumferentially.

"The Gen 2 OTW Paradise system is designed to offer optimal non-invasive ultrasound therapy for resistant hypertension patients to reduce resistant high blood pressure," said professor Marc Sapoval, chair of the cardiovascular radiology department at Hôpital Européen Georges-Pompidou, France. "The new features of Gen 2, including an over-the-wire 6Fr device and a quicker procedure, offers patients a superior treatment option to reduce their blood pressure.”

Mano Iyer, CEO of ReCor Medical, said, "The benefit of ReCor's ultrasound approach is three-fold. Firstly, Paradise is designed to penetrate much deeper into the tissue, up to 8 millimeters; secondly, Paradise delivers heat circumferentially, to target all of the renal nerves in one location; thirdly, Paradise does this while simultaneously cooling the artery wall's surface to protect the vessel.

Iyer continued, "Our unique approach is in stark contrast to RF, which is limited in its depth of penetration to just a few millimeters, due to inconsistent arterial wall contact, as well as its inability to heat circumferentially in any given location. In addition, RF technologies generate unnecessary heating at the level of the arterial wall. Data presented at TCT 2012 concluded that renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscores the Paradise ultrasound advantage."

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing